Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Evoq Remedies Limited is engaged in the marketing, trading, and distribution of pharmaceutical formulation products, serving a wide range of healthcare needs from antibiotic drugs to multivitamins.
The company began its operations in 2018, despite being incorporated in 2010, and has since established itself as a significant player in the pharmaceutical raw materials market.
Evoq Remedies markets approximately 120 products under its own brand name, emphasizing its strategy in private labelling while outsourcing manufacturing to third parties.
The company recently raised Rs. 9.72 Crore through a public issue to further strengthen its market position and possibly expand its distribution capabilities.
Commercial Services & Supplies
Trading & Distributors
6 Cr
High Risk
-26.3
20.3
—
0.1
6.11
2.27
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Evoq Remedies Ltd (EVOQ) is currently trading at 2.56 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Evoq Remedies Limited is engaged in the marketing, trading, and distribution of pharmaceutical formulation products, serving a wide range of healthcare needs from antibiotic drugs to multivitamins. The company began its operations in 2018, despite being incorporated in 2010, and has since established itself as a significant player in the pharmaceutical raw materials market. Evoq Remedies markets approximately 120 products under its own brand name, emphasizing its strategy in private labelling while outsourcing manufacturing to third parties. The company recently raised Rs. 9.72 Crore through a public issue to further strengthen its market position and possibly expand its distribution capabilities.
Over the past 52 weeks, Evoq Remedies Ltd has traded between a low of ₹2.27 and a high of ₹6.11. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Evoq Remedies Ltd has a market capitalization of approximately 6.30. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Evoq Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -26.25 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6.30 Cr, Evoq Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Evoq Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Evoq Remedies Ltd is -26.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
3
Neutral
2
Bullish
9
Bearish
34
Neutral
3
Bullish
9
Bearish
31
Neutral
1
Bullish
0
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
11.07 | 7 Cr | 9.43 | 0.73 | 0.95 | 7.75 | 7.31 | 1.22 | ||
3.48 | 6 Cr | 21.33 | 0.22 | 0.00 | 0.96 | 0.87 | 1.04 | ||
2.56 | 6 Cr | -26.25 | 0.14 | 0.00 | -0.54 | -0.57 | -0.46 | ||
1.05 | 6 Cr | 48.46 | 0.58 | 0.00 | 1.27 | 1.72 | 1.11 | ||
7.45 | 6 Cr | 21.48 | 1.21 | 0.00 | 6.12 | 6.12 | 1.63 | ||
15.00 | 6 Cr | -50.17 | 2.03 | 0.00 | -4.19 | -3.54 | -3.39 | ||
16.00 | 6 Cr | -11.54 | 0.44 | 0.00 | -2.30 | 3.84 | 2.66 | ||
| Median: 7 Co. | — | 7.45 | 6 Cr | 9.43 | 0.58 | 0.00 | 0.96 | 1.72 | 1.11 |
CIRP Admission
NCLT Ahmedabad admitted a Section 9 petition by operational creditor Harbhole Agrotech against Evoq Remedies Ltd for alleged non-refund/non-supply of goods of Rs.1,95,00,000, declared moratorium and appointed Ms. Dipti N. Mundra as IRP.
CIRP admission
NCLT (Ahmedabad) admitted a Section 9 CIRP petition on 09‑Jun‑2026 against Evoq Remedies Ltd filed by operational creditor Harbhole Agrotech claiming Rs 1,95,00,000; Dipti Narayan Mundra appointed IRP and moratorium declared.
